The International Blood-Brain Barrier  (BBB) Consortium is directed from OHSU, and combines basic science, research and comprehensive patient care to treat patients with brain tumors.

OHSU has developed protocols and guidelines for opening the blood-brain barrier with input from the universities participating in the International BBB Consortium.

Coordinator

The International BBB Consortium is coordinated from OHSU by Nancy Doolittle, Ph.D., R.N.

Included universities and foundations

Ohio State University Medical Center

Department of Neurosurgery

Columbus, Ohio
Program Director
John McGregor, M.D. (614) 293-5440
Clinical Study Coordinator
Susan Bell, R.N., M.S. (614) 293-3143

Cleveland Clinic Foundation 

Cleveland, Ohio
Program Director
Gene H. Barnett, M.D. (216) 445-1379

Good Samaritan Hospital, Hatton Institute

Cincinnati, Ohio
Program Director
Robert Albright, M.D. (513) 936-5370
Clinical Study Coordinator
Nancee Albright, R.N. (513) 862-2251

University of Oklahoma Health Science Center

Oklahoma City, Oklahoma
Program Director
Mary Kay Gumerlock, M.D. (405) 271-4912
Clinical Study Coordinator
Carol Young, R.N. (405) 271-4912

University of Minnesota

Minneapolis, Minnesota
Program Director
Matthew Hunt, M.D. (612) 626-0975
Clinical Study Coordinator
Katie Halbert, R.N. (612) 624-8117

 

Hadassah-Hebrew University Medical Center

Jerusalem, Israel
Program Director
Tali Siegal, M.D. 972 2 677-6951 

 

University of Kentucky 

Lexington, Kentucky
Program Director
Byron Young, M.D. (859) 323-5864 

 

Centre Hospital Universitaire de Sherbrooke

Quebec, Canada
Program Director
David Fortin, M.D. (819) 346-1110 

 

Protocols currently open at BBBD Consortium centers

Primary Central Nervous System Lymphoma

A Phase I/II Study of Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin to the Treatment Regimen

• Oregon Health & Science University, IRB #1012
• Ohio State University Medical Center, IRB #2012C0025

Phase II Clinical Trial of Patients with High-Grade Glioma Treated with Intra-arterial Carboplatin-based Chemotherapy, Randomized to Treatment with or without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant against Severe Thrombocytopenia

• Oregon Health & Science University, IRB #922
• University of Minnesota, IRB #1106M01141

Anaplastic Oligodendroglioma

Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction with Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma

• Oregon Health & Science University, IRB #8507
• University of Minnesota, IRB #1010M91012

Central Nervous System Embryonal & Germ Cell Tumors

Phase I/II Study of Intra-arterial Melphalan Given with Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

• Oregon Health & Science University, IRB #5056
• University of Minnesota, IRB #1104M97944